Page 43 - Athersys Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. Athersys Announces Cooperation Agreement With HEALIOS K.K. February 16, 2021 GMT CLEVELAND--(BUSINESS WIRE)--Feb 16, 2021-- Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of...

The Cleveland-based developer of the MultiStem cell therapy announced Tuesday morning, Feb. 16, that Van Bokkelen has stepped down from the roles effective immediately. Van Bokkelen co-founded Athersys in 1995. Athersys said its board of directors has appointed William (B.J.) Lehmann, the company's president and chief operating officer, as interim CEO. The board 'intends to identify and select a CEO who can guide Athersys in the commercial stage,' the company said.

(2) DALLAS, TX / ACCESSWIRE / February 16, 2021 / According to new report added in Report Banana offerings, there are significant money making opportunities available in the regenerative medicine market. Companies planning to enter this market need to prepare and differentiate to maximize their return on investment. In terms of opportunities, the regenerative medicine market is expected to grow from $5,444 million in 2016, to $39,325 million by 2023; it is expected to grow at a CAGR of 32.2% during the forecast period. Regenerative medicines repair, replace, and regenerate tissues and organs ...

Share this article Share this article ResearchAndMarkets.com's offering. Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cell types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cel...

Press release content from Business Wire. The AP news staff was not involved in its creation. Global Mesenchymal Stem Cells Advances and Applications Market Report 2021 - ResearchAndMarkets.com February 12, 2021 GMT DUBLIN--(BUSINESS WIRE)--Feb 12, 2021-- As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well as over 1,100 MSC clinical trials underway worldwide. ADVERTISEMENT Current “hotspots” for MSC clinical t...